Meeting NewsVideo

VIDEO: New drug for dry eye shows promise in preliminary study

PARIS — Eric D. Donnenfeld, MD, speaks about ALG-1007 (Allegro Ophthalmics), a new integrin regulator that inhibits the complement cascade of inflammation in dry eye disease. The initial proof-of-concept first-in-human study shows promise.

PARIS — Eric D. Donnenfeld, MD, speaks about ALG-1007 (Allegro Ophthalmics), a new integrin regulator that inhibits the complement cascade of inflammation in dry eye disease. The initial proof-of-concept first-in-human study shows promise.

    See more from European Society of Cataract and Refractive Surgeons Meeting